These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12678858)

  • 1. Eplerenone, a new selective aldosterone blocker.
    McMahon EG
    Curr Pharm Des; 2003; 9(13):1065-75. PubMed ID: 12678858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
    McMahon EG
    Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
    Susic D; Varagic J; Frohlich ED
    Am J Physiol Heart Circ Physiol; 2010 Apr; 298(4):H1177-81. PubMed ID: 20118410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.
    Brennan BJ; Martin NE
    J Am Pharm Assoc (2003); 2004; 44(5):604-10; quiz 610-1. PubMed ID: 15496047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment option for heart failure patients: eplerenone.
    Southworth MR; Cavallari LH
    J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of aldosterone blockade.
    Weber MA
    Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone antagonism and hypertension.
    Conti CR
    Clin Cardiol; 2003 May; 26(5):209-10. PubMed ID: 12769246
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of a selective aldosterone blocker in mice with chronic heart failure.
    Wang D; Liu YH; Yang XP; Rhaleb NE; Xu J; Peterson E; Rudolph AE; Carretero OA
    J Card Fail; 2004 Feb; 10(1):67-73. PubMed ID: 14966777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
    Black HR
    Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone: a selective aldosterone blocker.
    Stier CT
    Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
    Takeda Y
    Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
    Hameedi A; Chadow HL
    Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
    Pfeffer MA
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):11-3. PubMed ID: 11504157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor antagonist for renal protection.
    Ma TK; Szeto CC
    Ren Fail; 2012; 34(6):810-7. PubMed ID: 22463731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.